# Global Blood Therapeutics
 (stock symbol: GBT) Logo in transparent PNG format

## Global Blood Therapeutics
 Logo large

### Global Blood Therapeutics
 Logo large Download PNG (15.27 KB)

![Global Blood Therapeutics
 Logo large Download PNG (15.27 KB)](/img/orig/GBT_BIG-4e5b8262.png)

## Global Blood Therapeutics
 Logo icon format

### Global Blood Therapeutics
 Logo icon format Download PNG (6.04 KB)

![Global Blood Therapeutics
 Logo icon format Download PNG (6.04 KB)](/img/orig/GBT-ed1b2663.png)

## About Global Blood Therapeutics


Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

1. Website domain: gbt.com
2. Employees: 457
3. Marketcap: $4.62 Billion USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
